Diclofenac Potassium price index

Diclofenac Potassium price December 2025 and outlook (see chart below)

• India:US$8.3/KG, -1.2% down

Business Analytiq assumes no responsibility or liability for any errors or omissions in the content of this site. The information contained in this site is provided on an “as is” basis with no guarantees of completeness, accuracy, usefulness, or timeliness.

Diclofenac Potassium price index

This post is a summary of the Diclofenac Potassium price developments. The price developments of Diclofenac Potassium are expressed in US$ prices converted FX rates applicable at the time when the price was valid. Diclofenac Potassium price index developments are calculated from multiple separate sources of data to ensure statistical accuracy.

The outlook for Diclofenac Potassium prices is generated from different inputs including:

• Very recent price developments of immediate cost drivers of Diclofenac Potassium prices
• Recent price developments of underlying feedstocks which drive the price of Diclofenac Potassium
• Market futures for both cost drives and feedstocks of Diclofenac Potassium prices
• Adjustment of current supply/demand imbalances in the Diclofenac Potassium market
• Longer term trends in likely demand conditions

What is Diclofenac Potassium and what is it used for

Diclofenac Potassium is the potassium‑salt form of Diclofenac, a non‑steroidal anti‑inflammatory drug (NSAID) belonging to the phenylacetic acid derivatives.

It works by inhibiting cyclooxygenase (COX‑1 and COX‑2) enzymes and thereby reducing prostaglandin synthesis, which mediates inflammation, pain and fever.

Clinically, diclofenac potassium is used for relief of mild to moderate pain, inflammation, signs and symptoms of osteoarthritis and rheumatoid arthritis, primary dysmenorrhea (menstrual pain), and acute pain conditions.

The potassium form is noted for a faster onset of action compared to the sodium salt form, making it more suitable for acute pain settings.

How is Diclofenac Potassium produced

The production of diclofenac potassium involves first the synthesis of diclofenac (the free acid or a precursor salt) and then conversion to the potassium salt form. According to APIs (active pharmaceutical ingredients) regulatory and supplier directories, diclofenac potassium (CAS 15307‑81‑0) is produced by a number of specialised API manufacturers globally.

Although full public details of the synthetic chemical route are proprietary, literature and patent disclosures indicate that the process may include steps of anilino phenylacetic acid derivatisation, salt formation with potassium, and subsequent crystallisation and purification for pharmaceutical use.

Manufacturers list “wet granulation” and film‑coated tablet formulation steps for the final dosage forms incorporating diclofenac potassium.

Additionally, the API manufacturing is subject to Good Manufacturing Practice (GMP) regulations, and numerous companies in India, China, Taiwan, Italy and other countries serve as API suppliers.

How large is the global market for Diclofenac Potassium and where is it produced

The global market for diclofenac potassium is estimated at roughly **USD 1.6 billion in 2022** for this salt form, with growth driven by ageing populations and rising prevalence of chronic pain and inflammatory conditions.

Other market research reports provide varied estimates: for example, one report places the size at USD 2.1 billion in 2023, projected to reach about USD 3.5 billion by 2032 (CAGR ~5.6 %).

In terms of production and supply, the API is manufactured in multiple countries: India, China, Taiwan, Italy and other locations have significant output of diclofenac potassium API.

For example, Indian companies are listed among the key API producers. Chinese manufacturing hubs (e.g., in Jiangsu province) are referenced as important for NSAID and diclofenac‑type production.

Thus the production is global, with significant generics manufacturing in Asia, supplying finished generic tablets for many markets worldwide.